Retinoic acid (RA) and its metabolite 13-cis-retinoic acid have emerged as agents for the treatment of dermatological conditions. These agents and their analogues (retinoids) have also generated considerable interest because of their potential utility as cancer chemopreventive or chemotherapeutic agents. Although a promising class of compounds, their usefulness has been hampered by the relatively narrow therapeutic indices of most of these materials. The natural retinoids, as well as their analogues, are rapidly and extensively metabolized. Few of these metabolites retain useful biological activity with the exception of 13-cis-RA and the O-acyl glucuronide of RA, retinoyl-beta-glucuronide. THis glucuronide in particular has been suggested to be a less toxic, active metabolite of RA. Interestingly, preliminary studies suggest the O-glucuronide of the important synthetic retinoid 4-hydroxyphenylretinamide (4-HPR) also may represent a less toxic, effective metabolite of the parent molecule. However, it has yet to be shown whether these O-glucuronides are active metabolites or whether they are hydrolyzed back to the parent molecule at an appropriate rate to show useful properties.
The specific aims of this chemical program are: 1) the synthesis of substantial quantities of the O-glucuronides of RA and 4-HPR for detailed evaluations as well as their preparation in radiolabelled form to evaluate their uptake and fate, 2) the preparation of stable analogues of the above glucuronides to evaluate whether the intact forms of the glucuronides are uniquely effective metabolites, and 3) determine the stability and/or inhibitory activity of the analogues toward beta-glucuronidase.
The specific aims of the biological studies will be a comprehensive evaluation of the ability of these glucuronides and analogues to: 1) influence the growth of MCF-7 human breast cancer cells in vitro, 2) prevent DMBA induced mammary gland transformation in rats, and 3) be absorbed and metabolized by both the cells and experimental animals. Should any of these compounds show useful activities in these models for breast cancer, future goals would include further development of any compounds that appear to be promising.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA049837-03
Application #
2093476
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1991-01-01
Project End
1994-12-31
Budget Start
1993-01-01
Budget End
1994-12-31
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Cavanaugh, Kathryn R; Narayanasamy, Sureshbabu; Walker, Joel R et al. (2016) Improved Synthesis of the C-Glucuronide/Glycoside of 4-Hydroxybenzylretinone (4-HBR). J Carbohydr Chem 35:249-260
Clagett-Dame, Margaret; Knutson, Danielle (2011) Vitamin A in reproduction and development. Nutrients 3:385-428
Anding, Allyson L; Nieves, Nirca J; Abzianidze, Victoria V et al. (2011) 4-Hydroxybenzyl modification of the highly teratogenic retinoid, 4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-1-yl]benzoic acid (TTNPB), yields a compound that induces apoptosis in breast cancer cells and shows reduced terato Chem Res Toxicol 24:1853-61
Cooper, Jason P; Hwang, Kyunghwa; Singh, Hardeep et al. (2011) Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol 163:1263-75
Rahmaniyan, Mehrdad; Curley Jr, Robert W; Obeid, Lina M et al. (2011) Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. J Biol Chem 286:24754-64
Hruszkewycz, Damian P; Cavanaugh, Kathryn R; Takamura, Kathryn T et al. (2011) Efficient, Low-Cost Synthesis of Retinal (Vitamin A Aldehyde). Synthesis (Stuttg) 2011:2205-2207
Su, Bin; Mershon, Serena M; Stonerock, Laura A et al. (2008) 4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells. J Steroid Biochem Mol Biol 109:40-6
Anding, Allyson L; Chapman, Jason S; Barnett, Derek W et al. (2007) The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase- dependent and independent of the retinoic acid receptor. Cancer Res 67:6270-7
Mershon, Serena M; Anding, Allyson L; Chapman, Jason S et al. (2007) Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs. Bioorg Med Chem Lett 17:836-40
Walker, Joel R; Alshafie, Galal; Nieves, Nirca et al. (2006) Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide. Bioorg Med Chem 14:3038-48

Showing the most recent 10 out of 22 publications